Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review
Authors
Keywords
Quality of life, Patient-reported outcomes, Relapsed, Refractory, Multiple myeloma, Adverse events
Journal
SUPPORTIVE CARE IN CANCER
Volume 26, Issue 7, Pages 2075-2090
Publisher
Springer Nature
Online
2018-03-21
DOI
10.1007/s00520-018-4137-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A systematic review of health-related quality of life in longitudinal studies of myeloma patients
- (2017) Lene Kongsgaard Nielsen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment
- (2017) X Leleu et al. Blood Cancer Journal
- Palliative care from diagnosis to death
- (2017) Scott A Murray et al. BMJ-British Medical Journal
- Palliative care from diagnosis to death
- (2017) Scott A Murray et al. BMJ-British Medical Journal
- Treatment of relapsed and refractory multiple myeloma
- (2016) Pieter Sonneveld et al. HAEMATOLOGICA
- Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma
- (2016) A. Keith Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of relapsed and refractory multiple myeloma
- (2016) Pieter Sonneveld et al. HAEMATOLOGICA
- Treatment options for relapsed and refractory multiple myeloma
- (2015) A. K. Nooka et al. BLOOD
- How I treat fragile myeloma patients
- (2015) A. Larocca et al. BLOOD
- Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
- (2015) Katja Weisel et al. Clinical Lymphoma Myeloma & Leukemia
- Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
- (2015) J Laubach et al. LEUKEMIA
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network
- (2014) Natalie Callander et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
- (2014) K. W. Song et al. HAEMATOLOGICA
- Multiple Myeloma in the Older Adult: Better Prospects, More Challenges
- (2014) Tanya M. Wildes et al. JOURNAL OF CLINICAL ONCOLOGY
- Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
- (2013) S. Bringhen et al. HAEMATOLOGICA
- Living With Advanced But Stable Multiple Myeloma: A Study of the Symptom Burden and Cumulative Effects of Disease and Intensive (Hematopoietic Stem Cell Transplant-Based) Treatment on Health-Related Quality of Life
- (2013) Elaine Boland et al. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Review of health-related quality of life data in multiple myeloma patients treated with novel agents
- (2013) P Sonneveld et al. LEUKEMIA
- Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study
- (2013) Karin Jordan et al. SUPPORTIVE CARE IN CANCER
- Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry
- (2012) Floortje Mols et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
- (2012) Martin Hjorth et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- THE EFFECT OF ENGLISH-LANGUAGE RESTRICTION ON SYSTEMATIC REVIEW-BASED META-ANALYSES: A SYSTEMATIC REVIEW OF EMPIRICAL STUDIES
- (2012) Andra Morrison et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience
- (2012) Adrian Alegre et al. LEUKEMIA & LYMPHOMA
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
- (2011) P. M. Fayers et al. BLOOD
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989
- (2009) Michael Schaapveld et al. EUROPEAN JOURNAL OF CANCER
- Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations
- (2009) Ann Kristin Kvam et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- What changes in health-related quality of life matter to multiple myeloma patients? A prospective study
- (2009) Ann K. Kvam et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study
- (2008) Stephanie J. Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now